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Background: Therapy resistance remains one of the major challenges to improve the prognosis of patients with
pancreatic cancer. Chemoresistant cells, which potentially also display cancer stem cell (CSC) characteristics,
can be isolated using the side population (SP) technique. Our aim was to search for a SP in human pancreatic
ductal adenocarcinoma (PDAC) and to examine its chemoresistance and CSC(−like) phenotype.
Methods: Human PDAC samples were expanded in immunodeficient mice and first-generation xenografts analyzed
for the presence of a Hoechst dye-effluxing SP using flow cytometry (FACS). To investigate chemoresistance of
the SP, mice bearing PDAC xenografts were treated with gemcitabine and SP proportion determined. In addition,
the SP and the main tumour cell population (MP) were sorted by FACS for RNA extraction to profile gene
expression, and for culturing under sphere-forming conditions.
Results: A SP was identified in all PDAC samples, analyzed. This SP was more resistant to gemcitabine than the
other tumour cells as examined in vivo. Whole-genome expression profiling of the SP revealed upregulation of
genes related to therapy resistance, apoptotic regulation and epithelial-mesenchymal transition. In addition,
the SP displayed higher tumourigenic (CSC) activity than the MP as analyzed in vitro by sphere-forming capacity.
Conclusion: We identified a SP in human PDAC and uncovered a chemoresistant and CSC-associated phenotype.
This SP may represent a new therapeutic target in pancreatic cancer.
Trial registration: Clinicaltrials.gov NCT00936104
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Pancreatic cancer or ductal adenocarcinoma (PDAC)
remains a highly lethal disease. Despite improvements in
medical and surgical care, the overall 5-year survival still
has not exceeded 5% [1]. Resistance to chemotherapy is
a major cause of treatment failure in pancreatic cancer,
both in adjuvant setting after intended curative surgery
as well as in advanced inoperable stages [2]. Therefore,
PDAC’s chemoresistant cells are highly wanted targets
for new therapeutic strategies to eventually improve
overall survival.
Therapeutic resistance in pancreatic cancer is caused
by low permeability of the tumour micro-environment,
as well as by the efficient efflux of toxic agents [3,4].* Correspondence: baki.topal@uzleuven.be
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distribution, and reproduction in any mediumOne approach to isolate drug-effluxing cells is provided
by the side population (SP) technique [5]. SP cells are
identified on the basis of Hoechst-dye efflux capacity
because of the presence of multidrug resistance trans-
porters. Cells that expel the dye are visualized by dual-
wavelength flow cytometry (FACS) as a ‘Hoechst low’ tail
of cells, the SP, relative to a larger bulk of ‘Hoechst high’
cells, the main population (MP).
Recently, a SP has been identified in cultured pancre-
atic cancer cell lines and was found to be chemoresistant
to gemcitabine treatment as evaluated in vitro in these
cultured cell lines [3,6-8]. To date, it is not known
whether clinical human PDAC contains a SP and wether
this SP is resistant to gemcitabine when assessed in vivo.
In multiple types of cancer the SP is enriched in cells
displaying properties of cancer stem cells (CSC) [9,10].
By definition, CSC (also referred to as tumour-driving
cells) represent the tumour’s subpopulation with theCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tasis. CSC are also considered responsible for therapy
resistance and disease recurrence [11], and may therefore
represent interesting targets for new and more effective
treatment strategies [12]. Although still subject of debate,
(candidate) CSC populations are being identified in a
growing number of cancer types and their functional sig-
nificance has recently been strongly supported [13-15].
In pancreatic cancer, cells based on specific cell-surface
markers (i.e. CD24+CD44+ESA+ and CD133+ cells) have
been reported to possess CSC characteristics [12,16,17].
In the present study, we report for the first time that
human PDAC contains a SP and analyzed its resistance
to the current standard chemotherapeutic agent for pan-
creatic cancer, gemcitabine, using a PDAC xenograft
in vivo model. In addition, we performed whole-genome
expression analysis of PDAC SP cells, which may guide
to CSC-associated characteristics and to potential thera-
peutic targets. Finally, we explored in vitro whether the
PDAC SP is enriched in tumourigenic cells as a further
characteristic of CSC.
Methods
PDAC samples and xenografts
Between 2007 and 2010, PDAC surgical resection speci-
mens were obtained at the University Hospital Leuven
(Belgium) from patients after written informed consent
(see Table 1). The study was approved by the KU LeuvenTable 1 Patients’ characteristics with PDAC used for xenograf
Xenograft no. Sex Age (y) pG pT pN pM pR PNI V
101* F 45.5 2 4 1 0 1 1
110* M 77.8 2 3 0 0 1 1
112* F 77.8 2 3 1 0 0 1
127 M 52.9 2 2 1 0 0 1
128* M 53.6 2 3 1 0 1 1
136* M 78.4 2 3 1 0 0 0
151° M 45.9 2 3 1 0 0 1
169 F 80.5 2 3 1 0 0 0
174**,° M 66.9 2 3 0 0 0 1
178** F 53.2 3 4 1 0 0 1
199 M 52.2 3 3 0 0 1 1
207**,° F 67.0 2 3 0 0 0 0
218 F 62.6 3 3 1 0 0 1
223**,° F 57.3 2 2 1 0 0 1
229** F 73.2 3 3 1 0 0 1
235**,° F 57.4 1 3 1 0 1 1
241**,° F 74.6 2 3 0 0 0 1
* used for microarray analysis; ** used to investigate gemcitabine resistance; ° used for
Abbreviations: F: female; M: male; y: year; p: pathological; G: histopathological grade; T
PNI: perineural invasion; VI: vascular invasion; LVI: lymphovascular invasion; RCT: radio
m: month.ethical committee prior to patient recruitment, and
received the study number ML3452. Freshly resected
tumours were cut into small pieces (2*2 mm) and
implanted subcutaneously (s.c.) in the axilla of severe
combined immunodeficiency (SCID) mice (male, 6–
10 weeks old) to expand tumour material. Tumour
growth was evaluated with a caliper on a weekly basis
and volume calculated according to the formula: tumour
volume = (length x width2)/2 [18]. Mice bearing
tumours with a minimum volume of 150 mm3 were
euthanized and tumours were dissected for further
analysis. Only first-generation xenograft tumours were
used in the experiments described. Hematoxylin-Eosin
staining was performed on formalin-fixed sections from
original and xenograft tumours.
SP analysis
Xenograft tumours (n = 17) were dissociated into single
cells using collagenase type IV (1 mg/ml in Medium
199; Invitrogen, Grand Island, NY). Cells were incubated
with Hoechst33342 (Sigma-Aldrich, Bornem, Belgium)
at a final concentration of 5 μg/ml, and the SP was iden-
tified as a side branch of ‘Hoechst low’ cells using dual-
wavelength FACS analysis (FACSVantage SE, equipped
with FACS DIVA software, version 6.0; BD Biosciences,
Erembodegem, Belgium; Hoechst red with 675/20 nm
filter and Hoechst blue with 424/44 nm filter). Verap-
amil (100μM; Sigma-Aldrich) was added to verify the SPting
I LVI Preop RCT Postop RCT/CT OS (m) DFS (m) SP%
0 0 0 RCT 35.4 18.5 1.5
1 1 0 0 1.1 1.1 6.0
1 1 0 CT 10.1 3.6 6.8
0 0 0 CT 37.7 34.8 6.4
0 0 0 CT 11.2 10.2 6.8
0 0 0 0 37.8 24.5 6.1
1 1 0 CT 13.5 10.3 17.6
1 1 0 0 10.2 2.4 4.3
1 1 0 CT 43.3 19.8 2.7
0 1 0 CT 27.2 27.2 12.0
1 1 0 CT 23.5 4.9 5.0
0 0 0 CT 7.2 5.5 10.0
1 1 0 0 0.3 0.3 1.4
1 1 0 0 24.5 7.4 2.0
1 1 0 0 4.5 4.0 5.4
0 0 0 CT 19.6 7.7 2.1
0 0 0 0 6.9 2.9 2.7
sphere-formation assay.
: tumour size; N: lymph node metastasis; M: metastasis; R: resection margin;
chemotherapy; CT: chemotherapy; OS: overall survival; DFS: disease-free survival;
Van den broeck et al. BMC Cancer 2012, 12:354 Page 3 of 11
http://www.biomedcentral.com/1471-2407/12/354phenotype, as it results in the reduction of the side
branch by blocking the multidrug transporters. Propidium
Iodide (2μg/ml; Sigma-Aldrich) was used to exclude dead
cells. For further characterization, tumour cells were
immunostained for the endothelial marker CD31 and the
hematopoietic marker CD45. After Hoechst incubation,
fluorescein (FITC)-labeled anti-mouse or anti-human
CD31 and phycoerythrin (PE)-labeled anti-mouse or anti-
human CD45 antibodies (BD Biosciences), or PE-labeled
anti-human CD133 (Miltenyi Biotec, Bergisch Gladbach,
Germany) were added using dilutions according to the
manufacturer’s recommendations. Sorted SP and MP cells
were established as monolayers and subjected to Cyto-
Rich Red staining (BD Biosciences).
Treatment of mice bearing xenograft tumours with
gemcitabine
To investigate resistance of SP cells to gemcitabine, 7 dif-
ferent human PDAC samples were grown in SCID mice
(see Table 1). When the tumour reached a volume of ap-
proximately 200 mm3, one group of mice received gem-
citabine (Eli Lilly, Brussels, Belgium; 200 mg/kg body
weight intraperitoneally, 1 injection every 3 days, 6 injec-
tions in total) and the other group (bearing the corre-
sponding tumours) was injected with vehicle (0.9%
NaCl; control group). Tumour diameter was measured
every 3 days after the first injection. Three days after the
last injection, mice were euthanized and tumours ana-
lyzed to determine the proportion of SP cells as
described above. Gemcitabine was considered effective
when tumour volume decreased at least 50%.
Whole-genome expression profiling
For RNA extraction, 25000 SP and 25000 MP cells were
sorted by FACS into cold lysis solution (RNeasy Micro
Kit; Qiagen, Venlo, The Netherlands). RNA was extracted
according to the instructions of the manufacturer. RNA
quality and concentration were determined using Pico-
chips on a BioAnalyzer 2100 (Agilent Technologies,
Santa Clara, CA). Only samples with RNA Integrity
Number (RIN) ≥8.0 were used for gene expression pro-
filing by microarray analysis. After Baugh amplification,
Cy3 label was incorporated into the cRNA, which was
then hybridized onto whole-genome human 44 K oligo-
nucleotide arrays (G4112F, Agilent) [19,20].
Expression values were obtained using the Agilent fea-
ture extraction software (version 10.1.1.1) and subjected
to quantile normalization. Probes lacking a detection call
signal (n = 1666) were omitted from further analysis.
The log2-ratios for each SP-MP pair were compared
with the Limma (Linear Models for Microarra Data)
package of Bioconductor [21]. The contrast SP-MP was
tested with a moderate t-statistic (implemented in Limma).
The resulting p-values were corrected for multiple testingwith Benjamini-Hochberg to control false discovery rate.
The Database for Annotation, Visualization and Integrated
Discovery (DAVID, version 6.7, http://www.david.abcc.
ncifcrf.org) was used to uncover enriched function-related
gene groups by gene-annotation enrichment analysis and
to reveal enriched KEGG (Kyoto Encyclopedia of Genes
and Genomes) pathways. Significance was tested by the
EASE score, a modified Fisher’s exact p-value test to adjust
for multiple testing. Gene clusters with an enrichment
score of >1.5 were retained. To further visualize gene net-
works, the Search Tool for the Retrieval of Interacting
Genes (STRING, http://string.embl.de) was used.
Gene expression data are available from the Gene
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/
projects/geo/) through series accession number GSE36563.
Tumourigenic (CSC) activity as analyzed by in vitro
sphere formation
To investigate sphere-forming capacity, SP and MP sub-
populations were sorted by FACS from PDAC xenograft
tumours (n = 6; see Table 1), and 40000 cells of each
seeded in DMEM/F12 (Invitrogen), supplemented with
0.4% BSA and containing basic fibroblast growth factor
(bFGF; 10 ng/ml; R&D Systems, Minneapolis, MN), epi-
dermal growth factor (EGF; 20 ng/ml; R&D Systems),
insulin-transferrin-selenium (1:100; Invitrogen) and B27
(1:50; Invitrogen) [22]. The medium was renewed at day
3, and spheres were counted at day 7 to determine the
sphere-forming capacity.
Statistical analysis
Statistical analysis was performed using the Visual data
discovery software JMP9 (SAS, Cary, NC). A Wilcoxon
Test for nonparametric variables was applied to deter-
mine the statistical level of difference between values of
PDAC SP and MP and to compare the results from the
mouse group treated with gemcitabine and the control
group. Statistical significance was determined as p < 0.05,
and as p < 0.001 for the microarray analysis.
Results
Presence of a SP in human PDAC xenografts
Human PDAC samples (n = 17; Table 1) were expanded
by s.c. implantation, each in several SCID mice. All
tumours grew in at least one mouse, regardless of the
PDAC clinicopathological features or disease stage.
Xenograft tumours showed histological resemblance to
the original PDAC, although the stromal component
was less abundant in the xenograft than in the original
tumour (Figure 1A). In all tumours analyzed (n = 17), a
SP was identified, ranging from 1.4 to 17.6% of total cells
(median: 5.4%; Figure 1B-C; Table 1). Addition of verap-
amil during incubation with Hoechst decreased the SP
proportion to 0.4% (range: 0.1-5.6%), thus confirming






































Figure 1 A SP is present in human PDAC. (A) Hematoxylin-Eosin staining of an original PDAC sample (left) and the corresponding xenograft
tumour (right). A representative example is shown. Scale bar = 50 μm. (B) SP identification by FACS (left) and control of the SP phenotype with
verapamil (right). A representative example with SP proportions is displayed. Inserts show a SP cell (left) and a MP cell (right) after Cyto Rich Red
staining. Scale bar = 1 μm. (C) Boxplot of the SP proportion, with and without verapamil, of all PDAC xenografts analyzed (n = 17). *, p < 0.05.
(D) Analysis of CD45 and CD31 expression in the PDAC xenograft SP using FACS. A representative example is shown. Numbers represent the
percentage of CD45+ cells and of CD31+ cells within the SP.
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smaller than the MP cells and had a larger nucleus/
cytoplasm ratio, indicative of a poorly differentiated or
undifferentiated nature [3] (Figure 1B). No significant
correlation was found between the SP size and patients’
survival in this population of 17 PDAC (Table 1). Be-
cause it is known that the SP phenotype can co-purify
endothelial and hematopoietic cells [20,23], we further
analyzed the xenografts for CD31+ and CD45+ cells.
Human epitopes were not detected (data not shown) but
mouse CD45+ and CD31+ cells were found, indicating
that host cells were attracted and incorporated into the
growing human xenograft tumours. Yet, the proportion
of CD45+ and CD31+ cells in the SP was low (median:
4.1% and 4.5%, respectively; n = 10; Figure 1D).The SP is resistant to gemcitabine as assessed in vivo
Seven different PDAC samples were grown in SCID mice
(see Table 1). Treatment of mice with gemcitabine
affected growth of 4 out of 7 xenograft tumours, resulting
in an average volume reduction of 72% in comparison
with an average tumour expansion in the vehicle-treated
control group of 230% (p = 0.030) (Figure 2A-B). After
treatment, tumours were excised and analyzed for SP.
The tumour SP proportion was larger in mice treated
with gemcitabine than in the corresponding controls
(median 6.6% versus 2.7%, respectively; n = 7; p = 0.028;
Figure 2B-C). SP enrichment was even higher when only
considering the tumours that responded to gemcitabine
with tumour shrinkage (of at least 50%) (median: 4.7%
versus 1.3%, respectively; n = 4; Figure 2B). CD45+ and
AB
C
Figure 2 The SP in human PDAC is resistant to gemcitabine as
analyzed in vivo. (A) SCID mice with corresponding PDAC
xenograft tumours treated with vehicle (control or Co, left) or
gemcitabine (GEM, right). Tumours measured 276 mm3 and
266 mm3 in the control mouse and 144 mm3 and 123 mm3 in the
GEM-treated mouse, respectively. (B) Overview of the data,
indicating PDAC xenograft number, percent change in tumour
volume after treatment with vehicle (Co) or GEM (response to GEM
when >50% reduction), and proportion of SP in the tumours after
treatment. (C) Boxplot of SP proportion in the PDAC xenografts of
the vehicle-treated control mice (Co) and the mice treated with
GEM (n = 7). *, p < 0.05.
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bine (p = 0.21 and p = 0.66, respectively) when compared
to control mice.
Whole-genome expression analysis of the PDAC
xenograft SP reveals upregulation of genes related
to therapy resistance
To characterize the SP at the gene expression level,
whole-genome expression analysis was performed on SP
and MP cells sorted from 5 different xenograft tumours (see
Table 1). Microarrays with human genome oligonucleotideprobes were used, thereby excluding the detection of
mouse transcripts (such as from the infiltrating CD31+
and CD45+ SP cells). Comparison revealed that 145
probe sets, representing 121 genes, were differentially
expressed between the SP and MP (p < 0.001); 80 genes
were upregulated in the SP and 41 genes downregulated
(complete list in Additional file 1: Table S1; extract of
genes in Table 2, selected on the basis of relevance from
the literature and from DAVID analysis as below).
Gene-clustering analysis of all differentially expressed
genes (p < 0.001) by DAVID showed 3 functionally
related groups of genes enriched in the SP: one group of
transcription factors, one of adhesion molecules and one
of homeobox genes (Table 3). KEGG pathway analysis
revealed 3 significantly upregulated pathways in the
SP versus the MP, including ‘cancer’ and ‘adherens
junctions’ (Table 3). Two KEGG pathways were signifi-
cantly downregulated in the SP, including ‘cell adhesion
molecules’. Visualization of the interaction network of
SP-upregulated genes by STRING analysis (Figure 3)
reveals that genes involved in chemoresistance [ETS1,
KIT ligand (KITLG) or stem cell factor (SCF), SNAI2],
regulation of apoptosis (FASLG, GRB10, BCL2L11, ETS1,
SNAI2), epithelial-mesenchymal transition (EMT) (SNAI2,
LEF1) and tumourigenesis (oncogenes like FGF7, GATA1,
KITLG, ETS1) occupy a central position. Moreover, multi-
drug transporters, linked to chemoresistance and some
considered responsible for the SP phenotype, also show
a clear tendency of upregulation in the SP (ABCG2,
3.63 fold, p = 0.006; ABCA9, 3.66-fold, p = 0.003).
The SP is enriched in sphere-forming cells
Tumourigenic (CSC) activity was analyzed in vitro using
the sphere-forming assay [22]. SP and MP from xenograft
tumours were first depleted from the (murine) endothelial
and immune cells by FACS and then seeded in defined
culture conditions (see Methods). Viability of the sorted
SP and MP cells was identical (data not shown). The
CD45-/CD31- SP generated spheres in all experiments
(n = 6; median number of spheres: 16; range: 10–35;
Figure 4). In contrast, the CD45-/CD31- MP did not con-
sistently generate spheres (not in 2 out of the 6 experi-
ments) and the spheres obtained were lower in number
(range: 0–15; median: 8; p = 0.016 versus SP), less well-
formed, and smaller in size (Figure 4). These findings
indicate that SP cells have a higher sphere-forming cap-
acity than MP cells. It was not possible to assess the
propagation (self-renewal) capacity of the sphere-forming
cells because the number of spheres obtained was too low
and the dispersion did not yield enough (viable) cells.
Discussion
To date, SP analysis in pancreatic cancer has been lim-
ited to cultured cell lines [6-8,24,25]. In the present
Table 2 Selection of genes differentially expressed in the PDAC xenograft SP versus MP
Gene Symbol Genbank Accession no. Gene Name Fold SP/MP p-value
ZAP70 NM_001079 zeta-chain (TCR) associated protein kinase 70 kDa 24.25 0.00002
PRKCQ NM_006257 protein kinase C, theta 21.56 0.00008
FASLG NM_000639 Fas ligand (TNF superfamily, member 6) 19.56 0.00003
LEF1 NM_000639 lymphoid enhancer-binding factor 1 16.45 0.00009
PACSIN1 NM_020804 protein kinase C and casein kinase substrate in neurons 1 12.47 0.00015
MEOX2 NM_005924 mesenchyme homeobox 2 8.22 0.00060
STAT4 NM_003151 signal transducer and activator of transcription 4 7.46 0.00050
EMX2 NM_003151 empty spiracles homeobox 2 6.87 0.00006
SOX11 NM_003108 SRY (sex determining region Y)-box 11 6.19 0.00029
FGF7 NM_002009 fibroblast growth factor 7 (keratinocyte growth factor) 5.74 0.00072
FOXG1B NM_005249 forkhead box G1B 5.62 0.00019
PKNOX2 NM_022062 PBX/knotted 1 homeobox 2 5.58 0.00017
ITGB3 NM_000212 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 5.35 0.00062
KLF12 NM_007249 Kruppel-like factor 12 5.03 0.00048
SNAI2 NM_003068 snail homolog 2 (Drosophila) 4.99 0.00079
TIE1 NM_005424 tyrosine kinase with immunoglobulin-like and EGF-like domains 1 4.76 0.00019
IRX2 AY335940 iroquois homeobox protein 2 4.53 0.00010
EFNB2 NM_004093 ephrin-B2 4.23 0.00016
ETS1 NM_005238 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 3.95 0.00095
BCL2L11 NM_138621 BCL2-like 11 3.68 0.00019
GRB10 NM_001001555 growth factor receptor-bound protein 10 3.68 0.00034
NFIB NM_005596 nuclear factor I/B 3.46 0.00010
INHBB NM_002193 inhibin, beta B (activin AB beta polypeptide) 3.32 0.00059
TCF7L1 NM_031283 transcription factor 7-like 1 (T-cell specific, HMG-box) 3.14 0.00073
EPC2 NM_053001 enhancer of polycomb homolog 2 (Drosophila) 2.95 0.00090
GATA1 NM_002049 GATA binding protein 1 (globin transcription factor 1) 2.57 0.00082
KITLG NM_000899 KIT ligand 2.50 0.00052
ERRFI1 NM_018948 ERBB receptor feedback inhibitor 1 2.45 0.00074
CADM1 NM_014333 cell adhesion molecule 1 −22.84 0.00077
TREM2 NM_018965 triggering receptor expressed on myeloid cells 2 −9.90 0.00017
ALOX5AP NM_001629 arachidonate 5-lipoxygenase-activating protein −9.32 0.00017
PLA2G7 NM_005084 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) −7.66 0.00007
CD74 NM_004355 CD74 molecule, major histocompatibility complex, class II invariant chain −7.28 0.00006
MADCAM1 NM_130760 mucosal vascular addressin cell adhesion molecule 1 −6.53 0.00004
CD14 NM_130760 CD14 molecule −5.94 0.00038
CTSA NM_000308 cathepsin A −3.29 0.00068
CTSC NM_001814 cathepsin C −2.97 0.00085
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SP in human PDAC samples using first-generation xeno-
grafts, histologically resemblant to the original tumour
samples except for the stromal component. We showed,
using a xenograft in vivo model, that the SP is more
resistant to gemcitabine than the other tumour cells, and
therefore may represent a potential therapeutic target.The response rate of the xenograft tumours to gemcita-
bine (4 out of 7) was higher than the known response rate
in human patients (lower than 20%), which may be due
to the reduced stromal component in the xenografts, thus
improving drug delivery to the tumour cells (see [3,4]).
Whole-genome expression profiling of the SP demon-
strated the expression of genes involved in cancer
Table 3 Gene-function analysis of all differentially expressed genes between PDAC xenograft SP and MP using DAVID
A. ENRICHED GENE CLUSTERS
Gene group 1: Transcription Factors Enrichment Score: 1.78
1 TCF7L1 transcription factor 7-like 1 (T-cell specific, HMG-box)
2 SNAI2 snail homolog 2 (Drosophila)
3 CNOT4 CCR4-NOT transcription complex, subunit 4
4 ZBTB10 zinc finger and BTB domain containing 10
5 KLF12 Kruppel-like factor 12
6 ZFPM2 zinc finger protein, multitype 2
7 STAT4 signal transducer and activator of transcription 4
8 OSR2 odd-skipped related 2 (Drosophila)
9 IKZF2 IKAROS family zinc finger 2 (Helios)
10 PHF6 PHD finger protein 6
11 ZFHX4 zinc finger homeobox 4
12 SOX11 SRY (sex determining region Y)-box 11
13 CITED4 Cbp/p300-interacting transactivator, with Glu/
Asp-rich carboxy-terminal domain, 4
14 ARNTL aryl hydrocarbon receptor nuclear translocator-like
15 NFIB nuclear factor I/B
16 GATA1 GATA binding protein 1 (globin transcription factor 1)
17 ETS v-ets erythroblastosis virus E26 oncogene homolog 1
(avian)
18 LEF1 lymphoid enhancer-binding factor 1
Gene group 2: Adhesion Molecules Enrichment Score: 1.71
1 HLA-DPB1 major histocompatibility complex, class II, DP beta 1
2 MADCAM1 mucosal vascular addressin cell adhesion molecule 1
3 TREM2 triggering receptor expressed on myeloid cells 2
4 EFNB2 ephrin-B2
5 IGSF6 immunoglobulin superfamily, member 6
6 LRFN5 leucine rich repeat and fibronectin type III domain
containing 5
7 DSCAM Down syndrome cell adhesion molecule
8 JAM2 junctional adhesion molecule 2
9 MDGA1 MAM domain containing glycosylphosphatidylinositol
anchor 1
Gene group 3: Homeobox Genes Enrichment Score: 1.51
1 PKNOX2 PBX/knotted 1 homeobox 2
2 MEOX2 mesenchyme homeobox 2
3 SPIC Spi-C transcription factor (Spi-1/PU.1 related)
4 IRX2 iroquois homeobox 2
5 EMX2 empty spiracles homeobox 2
B. KEGG PATHWAYS
Upregulated in SP
Number of genes genes
Arrhythmogenic rightventricular
cardiomyopathy
4 GJA1, ITGB3, LEF1, TCFL1
Pathways in cancer 6 TCF7L1, KITL, FASL, LEF1, FGF7, ETS1
Adherens junction 3 LEF1, SNAI2, TCF7L1
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Table 3 Gene-function analysis of all differentially expressed genes between PDAC xenograft SP and MP using DAVID
(Continued)
Downregulated in SP
Number of genes genes
Lysosome 3 CTSA, CTSC, SLC11A1
Cell adhesion molecules (CAMs) 3 CADM1, HLA-DPB1, MADCAM1
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cancers, the proto-oncogene ETS1 plays a role in che-
moresistance and invasion [26]. In PDAC cell lines, ETS1
expression has been linked to gemcitabine resistance and
to invasiveness by induction of matrix metalloproteinase
(MMP) 2 [27]. We also found upregulation of MMP2
in the PDAC SP, although at the border of statistical sig-
nificance (3.12 fold; p = 0.003). Equally, KITLG (SCF)
increases invasive capacity in PDAC cell lines, as well as
cell proliferation [28,29]. The zinc finger transcription
factor SNAI2 (SLUG) is involved in chemo- and radiore-
sistance (e.g. through anti-apoptotic mechanisms) [30].Figure 3 Interaction network of genes upregulated in the human PDA
xenograft SP versus the MP (displayed as ‘evidence view’, i.e. only connecteMoreover, SNAI2 is a core regulator of EMT, a key
process in cancer pathogenesis and tumour progression
by which epithelial cells acquire a mesenchymal pheno-
type with invasive and migratory properties. EMT is con-
sidered to play an important role in tumour resistance
and metastasis. The SP of the pancreatic cell line PANC-
1 has been shown to possess superior potential for EMT
when compared to the MP [24]. Recently, SNAI2 was
shown to promote EMT, invasion and metastasis in a pan-
creatic cancer cell line [31,32]. EMT involves the downre-
gulation of cell adhesion molecules like E-cadherin. In the
present study, E-cadherin was significantly downregulatedC SP. STRING analysis of genes upregulated in the human PDAC
d nodes are shown).
AB
Figure 4 The human PDAC SP displays higher sphere-forming capacity than the MP. (A) Spheres grown from CD45-/CD31- SP cells (left)
and CD45-/CD31- MP cells (right) sorted from human PDAC xenografts. Representative examples are shown. Scale bar = 50 μm. (B) Boxplot of the
number of spheres obtained (n = 6). *, p < 0.05.
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SNAI2 can act as a transcriptional repressor of E-cadherin.
However, in pancreatic cancer cell lines, SNAI2 was
found only a weak suppressor of E-cadherin [32], whereas
in human PDAC, no significant correlation could be
observed between SNAI2 and E-cadherin [32,33]. LEF1
(lymphoid enhancer factor 1), a nuclear transducer of the
Wnt signaling pathway, also plays a key role in EMT.
In addition, LEF1 expression in human pancreatic cancer
correlates with advanced tumour stages [34]. TCF7L1 is
known to form a complex with LEF1 to achieve DNA-
binding ability. Finally, other signaling proteins of the
Wnt pathway (Wnt7b, DVL1, FZD1, FZD4, FZD5) as
well as components of the TGFβ/BMP pathway (TGFβ1,
BMP1, BMPP2Ra, SMURF2) were upregulated in the SP
versus MP, although not reaching statistical significance
(0.001 < p < 0.05; data not shown).
Protection against apoptosis represents a further
mechanism of therapy resistance. In our current study,
BCL2L11 and FASLG are upregulated in the SP. In stud-
ies with pancreatic cancer cell lines, BCL2L11 has been
correlated with apoptotic resistance as well as with
metastatic potential [35,36]. FASLG may regulate
immune evasion of tumour cells by inducing apoptosis
in cytotoxic T lymphocytes. FASLG has been reported to
play a role in the aggressiveness of PDAC, potentially
through this immune escape mechanism [37].Finally, the multidrug transporter ABCG2 is highly
expressed in the SP, suggesting a role in chemoresistance
and at the same time supporting the SP phenotype
which is, at least partially, linked to activity of this
pump. In pancreatic cancer cell lines, ABCG2 was also
found to be upregulated in the SP [6,8] and associated
with chemotherapy resistance [38]. In addition, ABCA9,
another membrane transporter linked to chemoresis-
tance in some cancers like malignant melanoma [39],
was found upregulated in the PDAC SP in our study.
In multiple types of cancer, the SP displays properties
reminiscent of CSC. In the present study, we show that
the SP of PDAC is enriched in cells that generate spheres.
Although sphere formation is regarded as an in-vitro
assay for CSC (tumourigenic) activity (see e.g. [22]), it
should be noted that this link is not always present as
reported, for instance, in high-grade glioma [40]. In order
to demonstrate tumourigenic (CSC) activity of the PDAC
SP, further study is needed that analyzes in-vivo tumour
growth after implantation of the (purified) population in
immunodeficient mice. Given the essential interactions
of cancer cells with their microenvironment for tumour
development, transplantation within the pancreas would
be most appropriate but technically highly demanding.
Yet, some expression characteristics may already suggest
a CSC(−like) phenotype including expression of genes
associated with chemoresistance (see above), with the
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has recently been uncovered as a key promoter of the
generation and activity of CSC [41]. Moreover, KITLG
(SCF) has been linked to CSC in prostate [42] and lung
cancer [43]. In the present study, expression of the previ-
ously proposed CSC membrane markers in pancreatic
cancer (i.e. CD24+CD44+ESA+ [16,44] and CD133+ [17])
was not found upregulated in the PDAC xenograft SP, nei-
ther in microarray analysis, nor in flow-cytometric examin-
ation (1.0% CD133+ cells in the SP and 0.7% in the MP;
n = 2) (data not shown). Noteworthy, expression of the
two previously defined sets of markers (CD24+CD44+ESA+
and CD133+) did also not completely, or only minimally,
overlap (10-40%) [16]. Thus, CSC in pancreatic cancer, and
the link with the SP, need further investigation.
Conclusions
Our study revealed the presence of a SP in human
PDAC, displaying chemoresistance and CSC-associated
activity, as well as expression of genes involved in both
processes. SP cells thus may represent interesting targets
for new and more efficient therapeutic strategies. Che-
moresistance, anti-apoptosis and EMT genes identified
may guide us to potential molecular targets.
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